Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Change in Account Payables: 2017-2024

Historic Change in Account Payables for Solid Biosciences (SLDB) over the last 8 years, with Dec 2024 value amounting to $815,000.

  • Solid Biosciences' Change in Account Payables rose 508.21% to $815,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $2.2 million, marking a year-over-year increase of 388.61%. This contributed to the annual value of $2.2 million for FY2024, which is 388.61% up from last year.
  • As of Q4 2024, Solid Biosciences' Change in Account Payables stood at $815,000, which was down 11.22% from $918,000 recorded in Q3 2024.
  • In the past 5 years, Solid Biosciences' Change in Account Payables registered a high of $2.7 million during Q1 2023, and its lowest value of -$5.9 million during Q4 2022.
  • Moreover, its 3-year median value for Change in Account Payables was $210,500 (2022), whereas its average is -$317,083.
  • Per our database at Business Quant, Solid Biosciences' Change in Account Payables tumbled by 1,136.14% in 2022 and then soared by 3,766.20% in 2023.
  • Solid Biosciences' Change in Account Payables (Quarterly) stood at -$829,000 in 2020, then soared by 168.76% to $570,000 in 2021, then slumped by 1,136.14% to -$5.9 million in 2022, then skyrocketed by 102.27% to $134,000 in 2023, then spiked by 508.21% to $815,000 in 2024.
  • Its Change in Account Payables stands at $815,000 for Q4 2024, versus $918,000 for Q3 2024 and $1.1 million for Q2 2024.